Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Abstract Background Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs. placebo in ≥ fourth-line advanced GIST. Here, we report prespecifi...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Patrick Schöffski, Suzanne George, Michael C. Heinrich, John R. Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2022-12-01
Saila:	BMC Cancer
Gaiak:	Gastrointestinal stromal tumors Ripretinib Patient-reported outcome measures Quality of life Alopecia
Sarrera elektronikoa:	https://doi.org/10.1186/s12885-022-10379-9
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!